טוען...
Safety concerns about intravenous iron therapy in patients with chronic kidney disease
Anaemia in chronic kidney disease (CKD) is managed primarily with erythropoiesis-stimulating agents (ESAs) and iron therapy. Following concerns around ESA therapy, intravenous (IV) iron is being administered more and more worldwide. However, it is still unclear whether this approach is safe at very...
שמור ב:
| הוצא לאור ב: | Clin Kidney J |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4792617/ https://ncbi.nlm.nih.gov/pubmed/26985378 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfv142 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|